The Retinal Disorder Drugs Market: 2021 – 2030 – Opportunities, Challenges, Strategies & Forecasts
Release Date: August 2021
Number of Pages: 229 Number of Tables and Figures: 48 Retinal disorders such as AMD (Age-Related Macular Degeneration) and diabetic eye disease can significantly impair vision by damaging the tissue layer at the back of the eye responsible for light detection. In severe cases, certain retinal disorders can even result in permanent blindness, making timely treatment critical. Retinal disorders are typically treated with drugs, laser treatment or surgery. Largely dominated by anti-VEGF (Vascular Endothelial Growth Factor) therapies, drugs remain the preferred approach to treat most cases of retinal disorders. The clinical pipeline is ripe as drug developers look to offer new treatment options with enhanced efficacy and increased intervals between treatment cycles. Retinal disorder drug sales are expected to account for more than $20 Billion by the end of 2021. The market is on path for future growth as a number of breakthrough therapies are expected to be approved between 2022-2025. The candidates in development – include long-acting VEGF inhibitors, dual inhibitors of Ang-2 (Angiopoietin-2)/VEGF, TKIs (Tyrosine Kinase Inhibitors), anti-integrin therapy, neuroprotective agents, Tie-2 activators, complement inhibitors, and gene and cell therapies. |
The “Retinal Disorder Drugs Market: 2021 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the retinal disorder drugs ecosystem including therapeutic areas, treatment options, key trends, market drivers, challenges, investment potential, leading therapies, delivery technologies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for retinal disorder drugs from 2021 through to 2030. The forecasts are segmented for 5 therapeutic categories, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and the retinal drug development pipeline data.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and the retinal drug development pipeline data.
For a Sample and Table of Contents please contact [email protected]
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
Company Wide License (Global Site): USD 6,500
Key Findings:
The report has the following key findings:
Topics Covered:
The report covers the following topics:
Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
Therapeutic Categories
Regional Markets
Country Markets
Key Questions Answered:
The report provides answers to the following key questions:
List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
4D Molecular Therapeutics
AbbVie
Adverum Biotechnologies
Aerie Pharmaceuticals
Aerpio Therapeutics
Alcon Laboratories
Alimera Sciences
Allegro Ophthalmics
Alteogen
Amgen
Ampio Pharmaceuticals
Apellis Pharmaceuticals
Astellas Pharma
Bausch + Lomb
Bayer
Benitec Biopharma
Bicycle Therapeutics
BioDiem
Bioeq IP
Biogen
BMS (Bristol-Myers Squibb)
Catalyst Biosciences
Cell Cure Neurosciences
Chengdu Kanghong Pharmaceuticals Group
Clearside Biomedical
Coherus BioSciences
Colby Pharmaceutical Company
Editas Medicine
EyeGate Pharmaceuticals
EyePoint Pharmaceuticals
FCDI (FUJIFILM Cellular Dynamics, Inc.)
Formycon
Galapagos
Gene Signal
Genentech
GenSight Biologics
Glycadia Pharmaceuticals
Graybug Vision
GSK (GlaxoSmithKline)
Healios
Helvetic BioPharma
Hemera Biosciences
Iconic Therapeutics
Intas Pharmaceuticals
Iveric Bio
Kala Pharmaceuticals
KalVista Pharmaceuticals
Kissei Pharmaceutical
Kodiak Sciences
Kubota Pharmaceutical Holdings
Lineage Cell Therapeutics
MacuCLEAR
MeiraGTx
Mimetogen Pharmaceuticals
Molecular Partners
NeuMedics
Neurotech Pharmaceuticals
Novartis
Novartis Ophthalmics
Novelion Therapeutics
NovelMed Therapeutics
OcuCure Therapeutics
Ocugen
Ocular Therapeutix
Ohr Pharmaceutical
ONL Therapeutics
Opthea
Oxford BioMedica
Oxurion
PanOptica
Pfenex
Pfizer
Quark Pharmaceuticals
Regeneron Pharmaceuticals
Regenxbio
RetroSense
Roche
RXi Pharmaceuticals Corporation
Samsung Bioepis
Sanofi
Santen Pharmaceutical Company
SciFluor Life Sciences
Senju Pharmaceutical Company
Sesen Bio
Shire
Spark Therapeutics
STADA Arzneimittel
Stealth BioTherapeutics
Stemedica Cell Technologies
Sumitomo Dainippon Pharma
Tyrogenex
U.S. FDA (Food and Drug Administration)
Vision Medicines
Xbrane Biopharma
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
Company Wide License (Global Site): USD 6,500
Key Findings:
The report has the following key findings:
- Retinal disorder drug sales are expected to account for more than $20 Billion by the end of 2021. The market is further expected to grow at a CAGR of approximately 7.5% over the next five-year period, eventually accounting for nearly $27 Billion in revenue by the end of 2025.
- The R&D pipeline for retinal disorder drugs is primarily focused on long-acting VEGF inhibition, dual inhibition of Ang-2 (Angiopoietin-2)/VEGF, TKIs (Tyrosine Kinase Inhibitors), anti-integrin therapy, neuroprotective agents, Tie-2 activation, complement inhibition, and gene and cell therapies.
- With several promising candidates in the pipeline, drug developers are closer to making the first breakthrough in the treatment for dry AMD, approval is expected between 2022 and 2025.
- The regulatory approval of next-generation anti-VEGF therapies will pave the way for patient-friendly treatment regimens – with less frequent dosing than currently approved therapies for wet AMD.
- Approval of Spark Therapeutics’ Luxturna, a novel gene therapy drug, has paved the way for transformative therapies in the retinal space. Several gene therapies are presently in late stage clinical development for conditions such as LHON (Leber Hereditary Optic Neuropathy), Stargardt disease and retinitis pigmentosa – as well as AMD and diabetic retinopathy.
Topics Covered:
The report covers the following topics:
- Retinal disorder drugs ecosystem
- Market drivers and barriers
- Role of drugs in retinal disorders and key trends
- Analysis of key drug classes and leading therapies
- Drug development pipeline for retinal disorders
- Advanced drug delivery technologies
- Future roadmap and value chain
- Profiles and strategies of over 80 leading ecosystem players, including retinal disorder drug developers
- Strategic recommendations for ecosystem players
- Market analysis and forecasts from 2021 till 2030
Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
Therapeutic Categories
- AMD (Age-Related Macular Degeneration)
- Wet AMD
- Dry AMD
- Diabetic Eye Disease
- Other Retinal Disorders
Regional Markets
- Asia Pacific
- Europe
- Middle East & Africa
- North America
- Latin & Central America
Country Markets
- Brazil
- Canada
- China
- Egypt
- France
- Germany
- Greece
- India
- Israel
- Italy
- Japan
- Mexico
- Netherlands
- Poland
- Portugal
- Russia
- Saudi Arabia
- South Africa
- South Korea
- Spain
- Switzerland
- Taiwan
- Turkey
- UK
- USA
Key Questions Answered:
The report provides answers to the following key questions:
- How big is the retinal disorder drugs opportunity?
- What trends, challenges and barriers are influencing its growth?
- How is the ecosystem evolving by segment and region?
- What will the market size be in 2021, and at what rate will it grow?
- Which countries and submarkets will see the highest percentage of growth?
- What are the prospects of complement inhibitors, neuroprotective agents, and other potential therapies for the treatment of dry AMD?
- How will next-generation anti-VEGF therapies impact the wet AMD treatment landscape?
- Who are the key market players, and what are their strategies?
- How will patent expirations of innovator drugs impact the market?
- What strategies should drug developers adopt to remain competitive?
List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
4D Molecular Therapeutics
AbbVie
Adverum Biotechnologies
Aerie Pharmaceuticals
Aerpio Therapeutics
Alcon Laboratories
Alimera Sciences
Allegro Ophthalmics
Alteogen
Amgen
Ampio Pharmaceuticals
Apellis Pharmaceuticals
Astellas Pharma
Bausch + Lomb
Bayer
Benitec Biopharma
Bicycle Therapeutics
BioDiem
Bioeq IP
Biogen
BMS (Bristol-Myers Squibb)
Catalyst Biosciences
Cell Cure Neurosciences
Chengdu Kanghong Pharmaceuticals Group
Clearside Biomedical
Coherus BioSciences
Colby Pharmaceutical Company
Editas Medicine
EyeGate Pharmaceuticals
EyePoint Pharmaceuticals
FCDI (FUJIFILM Cellular Dynamics, Inc.)
Formycon
Galapagos
Gene Signal
Genentech
GenSight Biologics
Glycadia Pharmaceuticals
Graybug Vision
GSK (GlaxoSmithKline)
Healios
Helvetic BioPharma
Hemera Biosciences
Iconic Therapeutics
Intas Pharmaceuticals
Iveric Bio
Kala Pharmaceuticals
KalVista Pharmaceuticals
Kissei Pharmaceutical
Kodiak Sciences
Kubota Pharmaceutical Holdings
Lineage Cell Therapeutics
MacuCLEAR
MeiraGTx
Mimetogen Pharmaceuticals
Molecular Partners
NeuMedics
Neurotech Pharmaceuticals
Novartis
Novartis Ophthalmics
Novelion Therapeutics
NovelMed Therapeutics
OcuCure Therapeutics
Ocugen
Ocular Therapeutix
Ohr Pharmaceutical
ONL Therapeutics
Opthea
Oxford BioMedica
Oxurion
PanOptica
Pfenex
Pfizer
Quark Pharmaceuticals
Regeneron Pharmaceuticals
Regenxbio
RetroSense
Roche
RXi Pharmaceuticals Corporation
Samsung Bioepis
Sanofi
Santen Pharmaceutical Company
SciFluor Life Sciences
Senju Pharmaceutical Company
Sesen Bio
Shire
Spark Therapeutics
STADA Arzneimittel
Stealth BioTherapeutics
Stemedica Cell Technologies
Sumitomo Dainippon Pharma
Tyrogenex
U.S. FDA (Food and Drug Administration)
Vision Medicines
Xbrane Biopharma
Our Research & Services |
Company |
MoreSubscribe for Latest Updates
Privacy Policy Disclosures Contact Us: [email protected] © 2025 SNS Research |